[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a765f877b02a605a235a412ef9ad999ae",
    "date": "2026-04-29",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "BioInvent_2026_Q1_SE.pdf",
    "text_chars": 52183,
    "sha256": "760646253561e826b991c899b5cef3cb5011cd352be5ea975efff2c17d64c8de",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 52183
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a487fe042126ce0a635def2e18fe5d002",
    "date": "2026-03-31",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "BioInvent_AR_2025_SE.pdf",
    "text_chars": 256078,
    "sha256": "efdccbf6e381225957a5e1d1ec52affbf07ebb50fb74e59db702d78f170bc384",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 179786
      },
      {
        "number": 2,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 76290
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7d93f053ec21ea8d08e351a192d6fb13",
    "date": "2026-02-26",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "BioInvent_Q4_2025_SE_Final.pdf",
    "text_chars": 64011,
    "sha256": "2d2727acac874bdb56f04acbbf3713f8b0f0cd5c63ed787ec40a0efb43b0e2a1",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 64011
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aaf62030777dde1c77b31a87decc7bd13",
    "date": "2025-10-29",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "BioInvent_Q3_2025_SE.pdf",
    "text_chars": 62170,
    "sha256": "aa97c4a88aa00b4c59994f746f13afa80d91ae6f51ceda1f600b038aab6b10e4",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 62170
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad1e4a43e2a0a70f0f24a5ec5030dc63b",
    "date": "2025-08-26",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "BioInvent_Q2_2025_SE_25_Augusti.pdf",
    "text_chars": 58410,
    "sha256": "eeb118e6a4b98d146a147018439761cecf789891a2277744590fe9fb3634b4ce",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 58410
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a93fd97dcbb69c06a98bbca3d7915bb01",
    "date": "2025-04-29",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "BioInvent_Q1_2025_SE.pdf",
    "text_chars": 56957,
    "sha256": "1bde995565aefd97353a9ada785e5cca9fced64bec2afdf11882a57e3c20d3ba",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 56957
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a81b8869e169747bb6eb2e0628e40d1c6",
    "date": "2025-04-04",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "BioInvent_AR_2024_SE_FINAL.pdf",
    "text_chars": 264240,
    "sha256": "01966b16031def74138efc849144ab9f45c904525300f2a9102c2b212247dd63",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 173839
      },
      {
        "number": 2,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 90399
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a4e46e0f8f95e50791a1efc8f5291065e",
    "date": "2025-02-27",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "BioInvent_Q4_2024_SE_Final.pdf",
    "text_chars": 63027,
    "sha256": "84f9d860cd29baa7e8faa628a471da8d32e7f31ae82dea8c5b947383677bad6d",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 63027
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a6f0722ec763ee02c5204b7bb5397531e",
    "date": "2024-10-31",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "BioInvent_Q3_2024_SE_Final.pdf",
    "text_chars": 64135,
    "sha256": "240176b82d9e84f7441753a319c02de449d5a7332909d6f0c16bdc5b0dc6d422",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 64135
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8c9a195497c084357930d08809bd444d",
    "date": "2024-08-29",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "BioInvent_Q2_2024_SE_Final.pdf",
    "text_chars": 65072,
    "sha256": "d87a7337d230474edc9255512d8e54ec176e2ae3b84aa7701ad9a01665f29f65",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 65072
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a02eeedd16b87572fea4fcf26b0036b83",
    "date": "2024-04-24",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "BioInvent_Q1_2024_SE_Final.pdf",
    "text_chars": 57224,
    "sha256": "2330486ede597bccc52644461b86760db9c1fe658e5b7f0be2699431033a1d77",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 57224
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a364100d8e3ca8d4be33a4e4eb14893b9",
    "date": "2024-04-04",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "BioInvent_AR_2023_SE.pdf",
    "text_chars": 253055,
    "sha256": "ed832cbeb1c10ece3a28450f47b49f338d8d1000b6e892991e84f7de368cbd3f",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 178243
      },
      {
        "number": 2,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 74810
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2412234949072bf59eac8ed22b6f1633",
    "date": "2024-02-22",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "BioInvent_Q4_2023_SE_21_Februari.pdf",
    "text_chars": 59858,
    "sha256": "2d189019d4289cc37d2484e846ec7a2e9eb1432009e169b77e34fc954b2566e7",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 59858
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a4d494801f274a18bac47cb87692323de",
    "date": "2023-10-26",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "BioInvent_Q3_2023_SE.pdf",
    "text_chars": 55909,
    "sha256": "f088a9b62e0de2fddf99459d82055070e218251219008656016d322dc900782e",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 55909
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a2ca36c1ee58d29ec5d20efefaa15b8d0",
    "date": "2023-08-30",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "BioInvent_Q2_2023_SE_Final.pdf",
    "text_chars": 57056,
    "sha256": "266f99d8d9266ae077b85ffdfca158499eff19828176065eb8f8742e17c79dad",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 57056
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/afbe6ff197068f6b7d4cbebf39b901af2",
    "date": "2023-04-26",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "BioInvent_Q1_2023_SE_Final.pdf",
    "text_chars": 53310,
    "sha256": "dd69154f612588fe8b682c646a8b90d596286f7c55ae6eb5c35ca0596f7bdbe9",
    "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 53310
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/bioinvent-international",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 16469,
    "sha256": "5873c73cf7fdf34a23e844d44b138c58d40a938295f60c9ff9c6f8fe40771260",
    "url": "/company/bioinvent-international/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/bioinvent-international/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/bioinvent-international/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/bioinvent-international/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/bioinvent-international/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 16469
      }
    ]
  }
]